v3.25.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2025
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

(2) Summary of Significant Accounting Policies

 

(a) Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP). The consolidated financial statements include the accounts of Cingulate and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

 

(b) Unaudited Interim Financial Information

 

The accompanying consolidated balance sheets as of June 30, 2025 and December 31, 2024, the consolidated statements of operations and comprehensive loss for the three and six-month periods ended June 30, 2025 and 2024, the consolidated statements of stockholders’ equity for the three and six-month periods ended June 30, 2025 and 2024, the consolidated statements of cash flows for the six-month periods ended June 30, 2025 and 2024, and the related interim disclosures are unaudited. These unaudited consolidated financial statements include all adjustments necessary, consisting of only normal recurring adjustments, to fairly state the financial position and the results of operations and cash flows for interim periods in accordance with U.S. GAAP. Interim period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The accompanying consolidated financial statements should be read in conjunction with the Company’s 2024 audited consolidated financial statements and the notes thereto.

 

 

(c) Concentration of Credit Risk

 

The Company maintains cash equivalent deposits, which at various times throughout the fiscal year exceeded the amounts insured by the Federal Deposit Insurance Corporation limit of $250,000 (without regard to reconciling items). Management monitors the soundness of these financial institutions and does not believe the Company is subject to any material credit risk relative to the uninsured portion of the deposits.

 

(d) Impairment of Long-lived Assets

 

The Company assesses the carrying value of its long-lived assets, including property and equipment, as well as lease right of use (ROU) assets, when events or circumstances indicate that the carrying value of such assets may not be recoverable. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by a comparison of the carrying amount of the assets to future undiscounted cash flows expected to be generated by the assets. If the sum of the expected future cash flows is less than the carrying amount, the Company would recognize an impairment loss. An impairment loss would be measured by comparing the amount by which the carrying value exceeds the fair value of the long-lived asset groups. No impairment was recognized during the six-month periods ended June 30, 2025 or 2024.

 

(e) Stock-Based Compensation

 

The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur. See additional information in Note 10.

 

(f) Segments

 

Operating segments are defined as components of an enterprise for which discrete financial information is available and regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company manages its business activities on a consolidated basis and operates as a single operating segment dedicated to the research and development and manufacturing of its product candidates. The Company’s CODM is its Chief Executive Officer. The CODM uses net loss, as reported in the Company’s Consolidated Statements of Operations and Comprehensive Loss, in evaluating performance of its segment and determining how to allocate resources of the Company as a whole, including investing in its research and development activities.

 

The measure used by the CODM for segment assets is reported in the Consolidated Balance Sheets as total consolidated assets.

 

 

The following table presents the operating results of the Company’s segment:

 

  2025   2024   2025   2024 
   Three Months Ended June 30,   Six Months Ended June 30, 
  2025   2024   2025   2024 
Operating expenses:                    
Research and development                    
Clinical operations  $763,860   $65,966   $1,871,334   $1,143,156 
Drug manufacturing and formulation   1,110,084    1,462,519    1,490,437    1,803,718 
Personnel   409,220    343,762    970,554    649,714 
Regulatory   417,775    8,846    591,240    91,490 
Total research and development   2,700,939    1,881,093    4,923,565    3,688,078 
General and administrative                    
Personnel   459,336    404,586    1,030,866    817,863 
Legal and professional fees   968,987    494,468    1,474,487    810,153 
Occupancy   88,359    73,846    149,986    174,533 
Insurance   174,449    241,524    370,045    483,048 
Other   257,904    110,663    407,060    180,722 
Total general and administrative   1,949,035    1,325,087    3,432,444    2,466,319 
Operating loss   (4,649,974)   (3,206,180)   (8,356,009)   (6,154,397)
Interest and other income (expense), net   (138,761)   (3,497)   (235,417)   (27,757)
Loss before income taxes   (4,788,735)   (3,209,677)   (8,591,426)   (6,182,154)
Income tax benefit (expense)   -    -    -    - 
                     
Net loss and comprehensive loss  $(4,788,735)  $(3,209,677)  $(8,591,426)  $(6,182,154)